Navigation Links
Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
Date:11/9/2007

peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for u
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
10. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
11. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... induce stress,but caring for children with diabetes this time ... and caregivers can visit, http://www.abbottdiabetescare.com to participate in ... how to best manage a child,s,diabetes during the holidays, ... ,Diabetes Fit Food, booklet for tips on healthy eating. ...
... REDWOOD CITY, Calif., Nov. 7 Threshold,Pharmaceuticals, Inc. ... for,the third quarter ended September 30, 2007. Net ... million compared to $16.7 million for the third ... development of our hypoxia-activated prodrug,platform for the treatment ...
... 13 at 1:30 p.m. (Pacific); ... at http://www.adventrx.com , SAN DIEGO, Nov. 7 ... research and development company,focused on commercializing proprietary product candidates ... financial results for,the three-month and nine-month periods ended September ...
Cached Biology Technology:New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 3Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 4Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... type of brain cancer, undergo neurosurgery to remove the ... largely on how rapidly the cancer recurs. Even though ... it is difficult to determine with certainty whether cancer ... aggressive treatment. Now a team from the University ...
... ACTON, Mass., Jan. 24, 2012 Psychemedics Corporation (NASDAQ: ... global leader for 25 years, announced today that the ... No. 8,084,215, to the company.  This patent focuses on ... without destroying the drugs.  The new patented method can ...
... 23, 2012) - With growing concern that excessive levels of ... pressure, kidney disease and diabetes researchers at the University of ... of Florida, set out to see if two common sweeteners in ... first few hours after ingestion. The study, recently published in ...
Cached Biology News:Team finds new way to image brain tumors and predict recurrence 2Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing 2CU School of Medicine researchers look at effects of 2 common sweeteners on the body 2
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
PFK-2 car (P-17)...
... ml Dynabeads Epoxy (4.5 m). Hydrophobic ... groups. Ideal for coupling of antibodies for ... initial coupling with covalent binding of primary ... groups (SH)) occurring within 16-20 hours. Coupling ...
LTBP-2 (7B10)...
Biology Products: